AmpVacs Project Aims to Develop Synthetic Influenza A Vaccine
Sanquin Blood Supply Foundation (Amsterdam, the Netherlands), the Netherlands Cancer Institute (Amsterdam, the Netherlands), and the Netherlands Vaccine Institute (Bilthoven, the Netherlands), have launched the AmpVacs project, which aims to develop a broadly protective synthetic influenza A vaccine component.
Sanquin Blood Supply Foundation (Amsterdam, the Netherlands), the Netherlands Cancer Institute (Amsterdam, the Netherlands), and the Netherlands Vaccine Institute (Bilthoven, the Netherlands), have launched the AmpVacs project, which aims to develop a broadly protective synthetic influenza A vaccine component. This component, in combination with classical antibody-stimulating vaccines, will induce protection against future influenza A threats.
The protection afforded by traditional influenza A vaccines is mediated by antibodies. In contrast, induction of cytotoxic T cells, the other effector arm of the adaptive immune system, is highly inefficient. However, efficient induction of cytotoxic T cell responses would be highly attractive in vaccine development, contrary to the molecular structures recognized by antibodies, which are the structures recognized by cytotoxic T cells that are conserved between different influenza A subtypes.
Based on this notion and the protective effect of cytotoxic T cells on influenza A infection in preclinical models, the AmpVacs project, designed to develop a fully synthetic influenza A vaccine component. T cell imaging technology developed by one of the partners for the generation of a database of T cell epitopes will be used for this purpose. This database will then be used for the development and evaluation of a fully synthetic influenza A vaccine component, using specific formulation technology from the partners.
Notably, as a major fringe benefit, the project will develop multiplexed T cell imaging technology for the diagnostics of human immune function.
The preclinical research phase of the project is being funded by a joint call initiative of three Dutch public–private partnerships, the BioMedical Materials program, the Centre for Translational Molecular Medicine, and Top Institute Pharma. The Dutch government is providing 50% of the of the €4.2 million budget, with the remaining 50% being provided by the partners in the project.
The Future of Cleanroom Construction: How Hybrid Solutions are Changing the Game
May 14th 2025Imagine a world where cleanroom facilities—essential for pharmaceutical manufacturing, biotechnology, and high-tech industries—are built with unparalleled speed, precision, and efficiency. That world is here, thanks to the hybrid construction approach. By blending traditional stick-built methods with modular and prefabricated solutions, companies are overcoming the limitations of conventional construction while ensuring compliance with stringent industry regulations. In this interview, we explore how hybrid cleanroom construction is transforming the industry, offering faster project timelines, improved quality control, and significant cost advantages. Join us as we delve into this game-changing approach with industry experts who are leading the charge in revolutionizing cleanroom infrastructure.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
